BRICS Cancer Radiation Therapy Market Outlook (2021–2031)

Escalating Global Cancer Rates

Cancer incidence is rising rapidly across the BRICS countries due to aging populations, urbanization, and lifestyle shifts such as dietary changes, smoking, and reduced physical activity. Common cancers include lung, breast, colorectal, prostate, and cervical cancer, with significant regional variation. Lung and esophageal cancers are prevalent in China, while breast and cervical cancers are prominent in India. This growing disease burden is driving increased demand for effective cancer treatments, including both external and internal beam radiation therapy.

Healthcare infrastructure in BRICS countries is expanding, but disparities exist between urban centers and rural areas. Major cities have advanced oncology centers offering modern radiation therapy, while smaller towns face limited access. As more patients are diagnosed at stages where surgery is insufficient, radiation therapy becomes a critical component of comprehensive cancer care, both as a primary treatment and as adjuvant therapy alongside chemotherapy or surgery.

Governments and private healthcare providers are investing in oncology facilities to meet rising demand. External beam radiation therapy is widely adopted due to its versatility, while internal beam (brachytherapy) is used for prostate, cervical, and gynecological cancers, particularly in India and Brazil. The growing prevalence of cancer across BRIC countries continues to act as a strong market driver for radiation therapy adoption.

Personalized Medicine: A Rising Trend

Personalized medicine is gaining traction across BRICS countries as patients and providers seek tailored cancer treatments that improve outcomes and reduce side effects. Precision approaches, including molecular profiling and image-guided radiation therapy, are being adopted in urban hospitals in Brazil, Russia, India, and China. These advancements allow clinicians to customize treatment doses based on tumor location, type, and patient-specific factors.

In external beam radiation therapy, technologies such as intensity-modulated radiation therapy (IMRT) and stereotactic body radiotherapy (SBRT) are expanding rapidly, particularly in China and Brazil, where large patient populations demand highly efficient and targeted treatments. Internal beam radiation therapy is being personalized, especially for cancers common in BRICS countries, including cervical, prostate, and head & neck cancers.

Collaborations with international oncology organizations, combined with government initiatives in India and China, are helping train specialists and upgrade existing treatment facilities. Patients are becoming informed and are actively seeking therapies that minimize side effects while maximizing efficacy. This rising demand for personalized medicine is creating significant opportunities for radiation therapy equipment manufacturers, software providers, and healthcare systems across the BRICS market.

The "BRICS Cancer Radiation Therapy Market Size and Forecast (2021 - 2031)" report provides a detailed analysis of the market covering below areas:

• BRICS Cancer Radiation Therapy market size and forecast at regional and country levels for key market segments covered under the scope
• BRICS Cancer Radiation Therapy market trends, as well as market dynamics such as drivers, restraints, and key opportunities
• BRICS Cancer Radiation Therapy market analysis covering key market trends, regional framework, major players, regulations, and recent market developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the BRICS Cancer Radiation Therapy market
• Detailed company profiles, including SWOT analysis

The geographical scope of the BRIC Cancer Radiation Therapy market report is divided into: Russia, Brazil, South Africa, India, China, Egypt, Indonesia, Saudi Arabia, and the UAE. China held the largest share in 2024.

China leads the BRIC cancer radiation therapy market due to its expansive oncology infrastructure, strong research momentum, and ability to scale advanced technologies across a wide healthcare network. The country has established numerous high-capacity cancer centers equipped with sophisticated linear accelerators, precision imaging systems, and advanced planning platforms, enabling efficient delivery of complex radiotherapy techniques. China's strong domestic manufacturing capabilities in medical equipment further strengthen its position, allowing faster deployment, local servicing, and more predictable technology lifecycle management.

A major advantage is China's integrated ecosystem that connects clinical practice, academic research, and technology development. The National Cancer Institute routinely collaborates with universities and technology companies to advance imaging algorithms, adaptive radiotherapy models, and AI‑driven planning tools. This environment accelerates innovation and supports standardized clinical protocols across disease sites. Additionally, China's extensive patient volume contributes to deep expertise across tumor types, reinforcing its ability to refine workflows and optimize treatment practices. Digital transformation remains a core strategic focus, with hospitals investing in data-driven oncology platforms, imaging archives, and automated quality systems. These capabilities—combined with strong government support, scale-driven efficiency, and research intensity—solidify China's dominant leadership in the BRIC radiotherapy landscape.

• The report includes qualitative and quantitative data in the BRICS cancer radiation therapy market across type, cancer type, end user, and geography.
• The report starts with the key takeaways (chapter 2), highlighting the key trends and outlook of the BRICS Cancer Radiation Therapy market.
• Chapter 3 includes the research methodology of the study.
• Chapter 4 further includes ecosystem analysis.
• Chapter 5 highlights the major industry dynamics in the BRICS Cancer Radiation Therapy market, including factors that are driving the market, prevailing deterrents, potential opportunities, as well as future trends. Impact analysis of these drivers and restraints is also covered in this section.
• Chapter 6 discusses the BRICS Cancer Radiation Therapy market scenario, in terms of historical market revenues, and forecast till the year 2033.
• Chapters 7 to 10 cover BRICS Cancer Radiation Therapy market segments by type, cancer type, end user, and geography across Russia, Brazil, South Africa, India, China, Egypt, Indonesia, Saudi Arabia, and the UAE. They cover the market revenue, forecast, and factors driving the market.
• Chapter 11 describes the competitive analysis along with the heat map analysis for the key players operating in the market.
• Chapter 12 describes the industry landscape analysis. It provides detailed descriptions of business activities such as market initiatives, new developments, mergers, and joint ventures globally, along with a competitive landscape.
• Chapter 13 provides detailed profiles of the major companies operating in the BRICS Cancer Radiation Therapy market. Companies have been profiled on the basis of their key facts, business descriptions, products, financial overview, SWOT analysis, and key developments.
• Chapter 14, i.e., the appendix, is inclusive of a brief overview of the company, list of abbreviations, and disclaimer.

The BRICS Cancer Radiation Therapy market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the key developments in the BRICS cancer radiation therapy market are:

• In March2025, Accuray announced that it had completed the first 100 patient treatment regimens in China using its Tomo C Radiation Treatment Delivery System through a joint venture with CNNC‑Accuray, marking a milestone for the adoption of advanced radiotherapy technology in the Chinese oncology market.
• In June2024, Apollo Cancer Centres in India, in collaboration with Accuray, announced the launch of the India sub‑continent's first robotic stereotactic radiotherapy program centered on the CyberKnife S7 System at facilities in Chennai and Bangalore, aimed at training clinicians and expanding advanced radiotherapy treatment options in India.